<p>Tandem Diabetes Care（纳斯达克代码：TNDM - 获取免费报告）在周六发布给客户和投资者的研究报告中，被华尔街 Zen 的股票研究人员从 “卖出” 评级上调至 “持有” 评级。</p>
<p>获取 <strong>Tandem Diabetes Care</strong> 的提醒：</p>
<p>其他股票研究分析师最近也发布了关于该公司的研究报告。瑞银集团将 Tandem Diabetes Care 的目标价从 20.00 美元下调至 17.00 美元，并在 8 月 7 日的报告中对该股票给予 “中性” 评级。派珀·桑德勒将 Tandem Diabetes Care 的评级从 “增持” 下调至 “中性”，并在 8 月 7 日的研究报告中将该公司的目标价从 30.00 美元下调至 14.00 美元。巴克莱将 Tandem Diabetes Care 的目标价从 53.00 美元下调至 51.00 美元，并在 8 月 8 日的研究报告中对该公司给予 “增持” 评级。富国银行将 Tandem Diabetes Care 的目标价从 20.00 美元下调至 13.00 美元，并在 8 月 7 日的研究报告中对该公司给予 “等权重” 评级。最后，加拿大皇家银行在 9 月 29 日的研究报告中重申了 “买入” 评级，并对 Tandem Diabetes Care 的股票设定了 24.00 美元的目标价。五位研究分析师对该股票给予 “买入” 评级，十一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Tandem Diabetes Care 目前的共识评级为 “持有”，共识目标价为 22.19 美元。</p>
<p><strong>获取我们对 Tandem Diabetes Care 的最新分析</strong></p>
<h2>Tandem Diabetes Care 股价下跌 3.3%</h2>
<p>TNDM 股票在周五开盘价为 14.79 美元。该股票的 50 日移动平均价格为 12.62 美元，200 日移动平均价格为 16.44 美元。该公司的市值为 9.9936 亿美元，市盈率为-4.79，贝塔值为 1.48。Tandem Diabetes Care 的 52 周低点为 9.98 美元，52 周高点为 38.28 美元。该公司的债务与股本比率为 2.32，速动比率为 1.88，流动比率为 2.44。</p>
<p>Tandem Diabetes Care（纳斯达克代码：TNDM - 获取免费报告）最近在 8 月 6 日发布了其财报。这家医疗设备公司报告本季度每股收益为（0.48 美元），低于分析师的共识预期（0.40 美元）0.08 美元。该季度的营业收入为 2.4068 亿美元，而分析师预期为 2.3839 亿美元。Tandem Diabetes Care 的净利润率为-20.51%，股本回报率为-65.40%。该季度的营业收入较去年同期增长了 8.5%。在去年同期，该公司每股收益为（0.47 美元）。股票分析师预测 Tandem Diabetes Care 在本财年将发布-1.68 美元的每股收益。</p>
<h2>Tandem Diabetes Care 的内部买卖</h2>
<p>在相关消息中，首席财务官 Leigh Vosseller 在 8 月 8 日的交易中购买了 13,720 股该股票。该股票的平均购买成本为每股 10.89 美元，总价值为 149,410.80 美元。交易完成后，首席财务官直接持有该公司 25,580 股，价值约为 278,566.20 美元。这笔交易代表了他们持股的 115.68% 的增长。该交易已在证券交易委员会的备案中披露，相关信息可在 SEC 网站上找到。此外，首席执行官 John F. Sheridan 在 8 月 11 日的交易中购买了 10,000 股该股票。该股票的平均购买成本为每股 10.23 美元，总价值为 102,300.00 美元。交易完成后，首席执行官持有该公司 106,327 股，价值为 1,087,725.21 美元。这笔交易使他们的持股增加了 10.38%。该购买的披露信息可以在这里找到。1.90% 的股票由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金和其他机构投资者最近对 TNDM 的持仓进行了调整。Assetmark Inc.在第一季度将其在 Tandem Diabetes Care 的股份增加了 42.9%。Assetmark Inc.目前持有 1,750 股该医疗设备公司的股票，价值 34,000 美元，此前在该期间内购买了 525 股。CWM LLC 在第二季度将其在 Tandem Diabetes Care 的股份增加了 262.6%。CWM LLC 目前持有 2,796 股该医疗设备公司的股票，价值 52,000 美元，此前在该期间内购买了 2,025 股。布鲁克林投资集团在第一季度将其在 Tandem Diabetes Care 的股份增加了 417.8%。布鲁克林投资集团目前持有 3,397 股该医疗设备公司的股票，价值 65,000 美元，此前在该期间内购买了 2,741 股。Nisa Investment Advisors LLC 在第二季度将其在 Tandem Diabetes Care 的股份增加了 186.9%。Nisa Investment Advisors LLC 目前持有 4,171 股该医疗设备公司的股票，价值 78,000 美元，此前在该期间内购买了 2,717 股。最后，怀俄明州在第一季度将其在 Tandem Diabetes Care 的股份增加了 49.1%。怀俄明州目前持有 4,467 股该医疗设备公司的股票，价值 86,000 美元，此前在该期间内购买了 1,471 股。</p>
<h2>Tandem Diabetes Care 公司简介</h2>
<p>（获取免费报告）</p>
<p>Tandem Diabetes Care, Inc.是一家医疗设备公司，设计、开发和商业化技术解决方案，服务于美国及国际上的糖尿病患者。该公司的旗舰产品是 t:slim X2 胰岛素输送系统，这是一个用于管理胰岛素输送并在泵的主屏幕上直接显示连续血糖监测传感器信息的泵平台；以及 Tandem Mobi 胰岛素泵，这是一个自动胰岛素输送系统。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Tandem Diabetes Care</li>
<li>标普 500 指数股票向投资者传达了什么市场信息？</li>
<li>这家 AI 芯片巨头可能是市场下一个大赢家</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>博通与 OpenAI 达成协议：这对 AVGO 股票来说是一个巨大的胜利</li>
<li>3 只超市股票证明它们仍然是必需品</li>
<li>机构正在推动 CrowdStrike 的下一轮上涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Tandem Diabetes Care 吗？</h2>
<p>在你考虑 Tandem Diabetes Care 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Tandem Diabetes Care 并不在名单上。</p>
<p>虽然 Tandem Diabetes Care 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TNDM

<p>华尔街禅将 Tandem Diabetes Care（纳斯达克代码：TNDM）的评级从 “卖出” 上调至 “持有”。其他分析师的意见各异，瑞银将其目标价下调至 17 美元，派珀·桑德勒则下调至 14 美元。该股开盘价为 14.79 美元，下跌 3.3%，市值为 9.9936 亿美元。公司报告每股亏损 0.48 美元，未达到预期，但收入同比增长 8.5%。内部人士购入股票，首席财务官和首席执行官均购买了股份。共识评级维持在 “持有”，目标价为 22.19 美元</p>

<p>Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report issued to clients and investors on Saturday.</p>
<div class="lb-trans"><p>Tandem Diabetes Care（纳斯达克代码：TNDM - 获取免费报告）在周六发布给客户和投资者的研究报告中，被华尔街 Zen 的股票研究人员从 “卖出” 评级上调至 “持有” 评级。</p>
</div><p>Get <strong>Tandem Diabetes Care</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tandem Diabetes Care</strong> 的提醒：</p>
</div><p>Other equities research analysts also recently issued research reports about the company. UBS Group reduced their target price on Tandem Diabetes Care from $20.00 to $17.00 and set a &#34;neutral&#34; rating on the stock in a report on Thursday, August 7th. Piper Sandler cut Tandem Diabetes Care from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and dropped their price target for the company from $30.00 to $14.00 in a research note on Thursday, August 7th. Barclays dropped their price target on Tandem Diabetes Care from $53.00 to $51.00 and set an &#34;overweight&#34; rating for the company in a research note on Friday, August 8th. Wells Fargo &amp; Company dropped their price target on Tandem Diabetes Care from $20.00 to $13.00 and set an &#34;equal weight&#34; rating for the company in a research note on Thursday, August 7th. Finally, Canaccord Genuity Group reiterated a &#34;buy&#34; rating and issued a $24.00 price target on shares of Tandem Diabetes Care in a research note on Monday, September 29th. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $22.19.</p>
<div class="lb-trans"><p>其他股票研究分析师最近也发布了关于该公司的研究报告。瑞银集团将 Tandem Diabetes Care 的目标价从 20.00 美元下调至 17.00 美元，并在 8 月 7 日的报告中对该股票给予 “中性” 评级。派珀·桑德勒将 Tandem Diabetes Care 的评级从 “增持” 下调至 “中性”，并在 8 月 7 日的研究报告中将该公司的目标价从 30.00 美元下调至 14.00 美元。巴克莱将 Tandem Diabetes Care 的目标价从 53.00 美元下调至 51.00 美元，并在 8 月 8 日的研究报告中对该公司给予 “增持” 评级。富国银行将 Tandem Diabetes Care 的目标价从 20.00 美元下调至 13.00 美元，并在 8 月 7 日的研究报告中对该公司给予 “等权重” 评级。最后，加拿大皇家银行在 9 月 29 日的研究报告中重申了 “买入” 评级，并对 Tandem Diabetes Care 的股票设定了 24.00 美元的目标价。五位研究分析师对该股票给予 “买入” 评级，十一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Tandem Diabetes Care 目前的共识评级为 “持有”，共识目标价为 22.19 美元。</p>
</div><p><strong>Get Our Latest Analysis on Tandem Diabetes Care</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Tandem Diabetes Care 的最新分析</strong></p>
</div><h2>Tandem Diabetes Care Trading Down 3.3%</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 股价下跌 3.3%</h2>
</div><p>Shares of TNDM stock opened at $14.79 on Friday. The stock's fifty day moving average price is $12.62 and its two-hundred day moving average price is $16.44. The company has a market cap of $999.36 million, a PE ratio of -4.79 and a beta of 1.48. Tandem Diabetes Care has a fifty-two week low of $9.98 and a fifty-two week high of $38.28. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.88 and a current ratio of 2.44.</p>
<div class="lb-trans"><p>TNDM 股票在周五开盘价为 14.79 美元。该股票的 50 日移动平均价格为 12.62 美元，200 日移动平均价格为 16.44 美元。该公司的市值为 9.9936 亿美元，市盈率为-4.79，贝塔值为 1.48。Tandem Diabetes Care 的 52 周低点为 9.98 美元，52 周高点为 38.28 美元。该公司的债务与股本比率为 2.32，速动比率为 1.88，流动比率为 2.44。</p>
</div><p>Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The medical device company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.08). The business had revenue of $240.68 million during the quarter, compared to analyst estimates of $238.39 million. Tandem Diabetes Care had a negative net margin of 20.51% and a negative return on equity of 65.40%. The company's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.47) EPS. Equities analysts predict that Tandem Diabetes Care will post -1.68 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Tandem Diabetes Care（纳斯达克代码：TNDM - 获取免费报告）最近在 8 月 6 日发布了其财报。这家医疗设备公司报告本季度每股收益为（0.48 美元），低于分析师的共识预期（0.40 美元）0.08 美元。该季度的营业收入为 2.4068 亿美元，而分析师预期为 2.3839 亿美元。Tandem Diabetes Care 的净利润率为-20.51%，股本回报率为-65.40%。该季度的营业收入较去年同期增长了 8.5%。在去年同期，该公司每股收益为（0.47 美元）。股票分析师预测 Tandem Diabetes Care 在本财年将发布-1.68 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at Tandem Diabetes Care</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 的内部买卖</h2>
</div><p>In related news, CFO Leigh Vosseller bought 13,720 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $10.89 per share, with a total value of $149,410.80. Following the transaction, the chief financial officer directly owned 25,580 shares in the company, valued at approximately $278,566.20. This trade represents a 115.68% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, CEO John F. Sheridan bought 10,000 shares of the stock in a transaction that occurred on Monday, August 11th. The shares were bought at an average cost of $10.23 per share, with a total value of $102,300.00. Following the completion of the transaction, the chief executive officer owned 106,327 shares in the company, valued at $1,087,725.21. The trade was a 10.38% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.90% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Leigh Vosseller 在 8 月 8 日的交易中购买了 13,720 股该股票。该股票的平均购买成本为每股 10.89 美元，总价值为 149,410.80 美元。交易完成后，首席财务官直接持有该公司 25,580 股，价值约为 278,566.20 美元。这笔交易代表了他们持股的 115.68% 的增长。该交易已在证券交易委员会的备案中披露，相关信息可在 SEC 网站上找到。此外，首席执行官 John F. Sheridan 在 8 月 11 日的交易中购买了 10,000 股该股票。该股票的平均购买成本为每股 10.23 美元，总价值为 102,300.00 美元。交易完成后，首席执行官持有该公司 106,327 股，价值为 1,087,725.21 美元。这笔交易使他们的持股增加了 10.38%。该购买的披露信息可以在这里找到。1.90% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in TNDM. Assetmark Inc. lifted its stake in shares of Tandem Diabetes Care by 42.9% in the 1st quarter. Assetmark Inc. now owns 1,750 shares of the medical device company's stock valued at $34,000 after purchasing an additional 525 shares during the period. CWM LLC lifted its stake in shares of Tandem Diabetes Care by 262.6% in the 2nd quarter. CWM LLC now owns 2,796 shares of the medical device company's stock valued at $52,000 after purchasing an additional 2,025 shares during the period. Brooklyn Investment Group lifted its stake in shares of Tandem Diabetes Care by 417.8% in the 1st quarter. Brooklyn Investment Group now owns 3,397 shares of the medical device company's stock valued at $65,000 after purchasing an additional 2,741 shares during the period. Nisa Investment Advisors LLC lifted its stake in shares of Tandem Diabetes Care by 186.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,171 shares of the medical device company's stock valued at $78,000 after purchasing an additional 2,717 shares during the period. Finally, State of Wyoming lifted its stake in shares of Tandem Diabetes Care by 49.1% in the 1st quarter. State of Wyoming now owns 4,467 shares of the medical device company's stock valued at $86,000 after purchasing an additional 1,471 shares during the period.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近对 TNDM 的持仓进行了调整。Assetmark Inc.在第一季度将其在 Tandem Diabetes Care 的股份增加了 42.9%。Assetmark Inc.目前持有 1,750 股该医疗设备公司的股票，价值 34,000 美元，此前在该期间内购买了 525 股。CWM LLC 在第二季度将其在 Tandem Diabetes Care 的股份增加了 262.6%。CWM LLC 目前持有 2,796 股该医疗设备公司的股票，价值 52,000 美元，此前在该期间内购买了 2,025 股。布鲁克林投资集团在第一季度将其在 Tandem Diabetes Care 的股份增加了 417.8%。布鲁克林投资集团目前持有 3,397 股该医疗设备公司的股票，价值 65,000 美元，此前在该期间内购买了 2,741 股。Nisa Investment Advisors LLC 在第二季度将其在 Tandem Diabetes Care 的股份增加了 186.9%。Nisa Investment Advisors LLC 目前持有 4,171 股该医疗设备公司的股票，价值 78,000 美元，此前在该期间内购买了 2,717 股。最后，怀俄明州在第一季度将其在 Tandem Diabetes Care 的股份增加了 49.1%。怀俄明州目前持有 4,467 股该医疗设备公司的股票，价值 86,000 美元，此前在该期间内购买了 1,471 股。</p>
</div><h2>Tandem Diabetes Care Company Profile</h2>
<div class="lb-trans"><h2>Tandem Diabetes Care 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.</p>
<div class="lb-trans"><p>Tandem Diabetes Care, Inc.是一家医疗设备公司，设计、开发和商业化技术解决方案，服务于美国及国际上的糖尿病患者。该公司的旗舰产品是 t:slim X2 胰岛素输送系统，这是一个用于管理胰岛素输送并在泵的主屏幕上直接显示连续血糖监测传感器信息的泵平台；以及 Tandem Mobi 胰岛素泵，这是一个自动胰岛素输送系统。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Tandem Diabetes Care</li>
<li>What Do S&amp;P 500 Stocks Tell Investors About the Market?</li>
<li>This AI Chip Giant Could Be the Market’s Next Big Winner</li>
<li>How to Calculate Retirement Income: MarketBeat’s Calculator</li>
<li>Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>Institutions Are Fueling CrowdStrike’s Next Leg Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Tandem Diabetes Care</li>
<li>标普 500 指数股票向投资者传达了什么市场信息？</li>
<li>这家 AI 芯片巨头可能是市场下一个大赢家</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>博通与 OpenAI 达成协议：这对 AVGO 股票来说是一个巨大的胜利</li>
<li>3 只超市股票证明它们仍然是必需品</li>
<li>机构正在推动 CrowdStrike 的下一轮上涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE5ETQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=TNDM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tandem Diabetes Care Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Tandem Diabetes Care 吗？</h2>
</div><p>Before you consider Tandem Diabetes Care, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Tandem Diabetes Care 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Tandem Diabetes Care 并不在名单上。</p>
</div><p>While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tandem Diabetes Care 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Tandem Diabetes Care（纳斯达克股票代码：TNDM）的评级在 Wall Street Zen 被上调至持有